Ulviprubart

DB18281InvestigationalProtein Based Therapies

Ulviprubart: Overview.

Also known as
Anti-klrg1 (afucosylated, humanized igg1) · gamma1 heavy chain humanized (1-449) [VH humanized (Homo sapiens IGHV1-8*01 (81.6%) -(IGHD) -IGHJ5*01 (86.7%), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), C · immunoglobulin G1-kappa, anti-[Homo sapiens KLRG1(killer cell lectin like receptor G1, MAFA, CLEC15A)], humanized monoclonal antibody · Immunoglobulin G1, anti-(human killer cell lectin-like receptor subfamily G member 1) (human-Mus musculus monoclonal ABC008 γ1-chain), disulfide with human-Mus musculus monoclonal ABC008 κ-chain, dime
Code names
ABC-008

Resolves to

Compound
UNIIQT44II3WZPCAS2569434-60-0

What you can answer from here — as of April 23, 2025

4Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Ulviprubart, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In